🌟 Levodropropizine (CAS 99291-25-5) - Product Overview
Levodropropizine is a peripherally acting antitussive agent (molecular formula: C₁₃H₂₀N₂O₂, MW: 236.31) designed to treat acute dry cough caused by upper respiratory infections and bronchitis. As the S-enantiomer of dropropizine, it selectively inhibits sensory nerve endings in the airways, reducing cough reflex activation with minimal central side effects. This white crystalline powder (HPLC purity ≥99%) exhibits excellent stability under room temperature storage, ideal for oral solid and liquid formulations12.
🔑 Key Advantages
✔️ High Efficacy: Reduces cough frequency by >50% within 2 hours post-administration13.
✔️ Rapid Action: Achieves peak plasma concentration in 1-1.5 hours for quick symptom relief12.
✔️ Safety Profile: Low sedation risk (incidence <2%) compared to codeine-based antitussives13.
✔️ Solubility: Water solubility ≥20 mg/mL for flexible formulation development47.
📋 Applications
Cough Suppressants: First-line treatment for acute non-productive cough in adults and children.
Pediatric Formulations: Used in syrups and oral drops due to favorable tolerability.
Research: Tool for studying peripheral cough reflex mechanisms and enantiomer-specific drug effects.
🏅 Quality Certifications
Complies with USP/EP pharmacopeial standards for API purity.
Rigorously tested via HPLC (≥99%), GC, and FTIR for structural validation.
Manufactured in GMP-certified facilities with ISO 9001 compliance.
📈 Market Insights
The global antitussive drug market is projected to grow at 5.8% CAGR through 2030, driven by rising respiratory infections. Levodropropizine holds >15% market share in non-opioid cough suppressants, favored for its enantiomeric purity and pediatric safety.
China
